Sorin Group, a Netherlands-based company, has received US FDA approval for the launch the Smartview remote monitoring solution for patients with implanted cardiac rhythm management (CRM) devices.
Using the secure SMARTVIEW remote monitoring solution, physicians and nurses following patients with a Sorin Paradym RF device can access valuable cardiac data and alert messages from the device while the patient is at home.
In the US, Sorin had launched the Paradym RF VR and DR implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices in May 2012.
Paradym RF devices are the clinically proven ICDs that reduce RV pacing below 1%, offer the lowest recorded inappropriate shock rate and a combination of advanced diagnostic capabilities, early detection of cardiac disease progression, and patient convenience.
Once the system is installed at their home, the patients can use the Smartview system to transmit data electronically from their implanted cardiac device to their physicians.
Sorin Group CRM Business Unit president Stefano Di Lullo said that the introduction of Smartview remote monitoring in the US is an important milestone for Sorin as the company seeks to extend its technology offerings to more US healthcare providers and patients.
"We believe our intelligent devices and first-rate remote monitoring capabilities and service will continue to help us grow our business in the United States while, most importantly, saving lives and improving patient symptoms," Lullo added.
